Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery

Critical Care

Volumn 17, Issue 3, 2013, Pages

  Kim, In Kyoung ^a   Rhee, Chin Kook ^a   Yeo, Chang Dong ^a   Kang, Hyeon Hui ^a   Lee, Dong Gun ^a   Lee, Sang Haak ^a   Kim, Jin Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acute lung injury; imatinib; neutropenia recovery; nilotinib; platelet derived growth factor receptor (PDGFR)

Indexed keywords

CYCLOPHOSPHAMIDE; IMATINIB; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELOPEROXIDASE; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; INFLAMMATORY CELL; LUNG EDEMA; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; PHYSIOLOGY; RANDOMIZATION; TREATMENT OUTCOME;

ACUTE LUNG INJURY; ANIMALS; BENZAMIDES; DISEASE MODELS, ANIMAL; FEMALE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED ICR; NEUTROPENIA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RANDOM ALLOCATION; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 84879086917     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12786     Document Type: Article

References (44)

1. Kress JP, Christenson J, Pohlman AS, Linkin DR, Hall JB. Outcomes of critically ill cancer patients in a university hospital setting. Am J Respir Crit Care Med 1999, 160:1957-1961. 10.1164/ajrccm.160.6.9812055, 10588613.
2. Ewig S, Torres A, Riquelme R, El-Ebiary M, Rovira M, Carreras E, Rano A, Xaubet A. Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU. Eur Respir J 1998, 12:116-122. 10.1183/09031936.98.12010116, 9701425.
3. Blot F, Guiguet M, Nitenberg G, Leclercq B, Gachot B, Escudier B. Prognostic factors for neutropenic patients in an intensive care unit: respective roles of underlying malignancies and acute organ failures. Eur J Cancer 1997, 33:1031-1037. 10.1016/S0959-8049(97)00042-7, 9376183.
4. Azoulay E, Recher C, Alberti C, Soufir L, Leleu G, Le Gall JR, Fermand JP, Schlemmer B. Changing use of intensive care for hematological patients: the example of multiple myeloma. Intensive Care Med 1999, 25:1395-1401. 10.1007/s001340051087, 10660847.
5. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, GA ES, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008, 9:730-756. 10.1016/S1470-2045(08)70179-7, 18639491.
6. Rhee CK, Kang JY, Kim YH, Kim JW, Yoon HK, Kim SC, Kwon SS, Kim YK, Kim KH, Moon HS, Park SH, Kim HJ, Lee S, Song JS. Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies. Crit Care 2009, 13:R173. 10.1186/cc8149, 2811915, 19886984.
7. Rinaldo JE, Borovetz H. Deterioration of oxygenation and abnormal lung microvascular permeability during resolution of leukopenia in patients with diffuse lung injury. Am Rev Respir Dis 1985, 131:579-583.
8. Okubo Y, Nakazawa K. [Recombinant G-CSF and the interstitial pneumonia during MACOP-B therapy in two cases of non-Hodgkin's lymphoma]. Rinsho Ketsueki 1993, 34:473-477.
9. Demuynck H, Zachee P, Verhoef GE, Schetz M, Van den Berghe G, Lauwers P, Boogaerts MA. Risks of rhG-CSF treatment in drug-induced agranulocytosis. Ann Hematol 1995, 70:143-147. 10.1007/BF01682034, 7536476.
10. Lisukov IA, Kriuchkova IV, Kulagin AD, Gilevich AV, Ostanin AA, Shevela E, Chernykh ER. [The adult respiratory distress syndrome during the recovery of the neutrophil level after autologous bone marrow transplantation]. Ter Arkh 1998, 70:78-79.
11. Todeschini G, Murari C, Bonesi R, Pizzolo G, Verlato G, Tecchio C, Meneghini V, Franchini M, Giuffrida C, Perona G, Bellavite P. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest 1999, 29:453-457. 10.1046/j.1365-2362.1999.00474.x, 10354203.
12. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 2010, 18:6977-6986. 10.1016/j.bmc.2010.08.026, 20817538.
13. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008, 599:44-53. 10.1016/j.ejphar.2008.10.014, 18938156.
14. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, Zwerina J, Gay S, Schett G, Distler O, Distler JH. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008, 22:2214-2222. 10.1096/fj.07-105627, 18326784.
15. Berlin AA, Lukacs NW. Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med 2005, 171:35-39. 10.1164/rccm.200403-385OC, 15374841.
16. Loong HH, Yeo W. Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage. Hong Kong Med J 2008, 14:495-498.
17. Staub NC. Pulmonary edema. Physiol Rev 1974, 54:678-811. 10.1104/pp.54.5.678, 4601625.
18. Maunder RJ, Hackman RC, Riff E, Albert RK, Springmeyer SC. Occurrence of the adult respiratory distress syndrome in neutropenic patients. Am Rev Respir Dis 1986, 133:313-316.
19. Laufe MD, Simon RH, Flint A, Keller JB. Adult respiratory distress syndrome in neutropenic patients. Am J Med 1986, 80:1022-1026. 10.1016/0002-9343(86)90659-5, 3728499.
20. Azoulay E, Darmon M, Delclaux C, Fieux F, Bornstain C, Moreau D, Attalah H, Le Gall JR, Schlemmer B. Deterioration of previous acute lung injury during neutropenia recovery. Crit Care Med 2002, 30:781-786. 10.1097/00003246-200204000-00010, 11940745.
21. Parsey MV, Tuder RM, Abraham E. Neutrophils are major contributors to intraparenchymal lung IL-1 beta expression after hemorrhage and endotoxemia. J Immunol 1998, 160:1007-1013.
22. Abraham E, Bursten S, Shenkar R, Allbee J, Tuder R, Woodson P, Guidot DM, Rice G, Singer JW, Repine JE. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med 1995, 181:569-575. 10.1084/jem.181.2.569, 2191876, 7836912.
23. Reutershan J, Basit A, Galkina EV, Ley K. Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005, 289:L807-815. 10.1152/ajplung.00477.2004, 15951336.
24. Abraham E. Neutrophils and acute lung injury. Crit Care Med 2003, 31:S195-199. 10.1097/01.CCM.0000057843.47705.E8, 12682440.
25. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
26. Siegbahn A, Hammacher A, Westermark B, Heldin CH. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest 1990, 85:916-920. 10.1172/JCI114519, 296510, 2155930.
27. Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, Greenheck JR, Chen B, Bitterman PB. Acute lung injury. Pathogenesis of intraalveolar fibrosis. J Clin Invest 1991, 88:663-673. 10.1172/JCI115351, 295409, 1864975.
28. Budinger GR, Chandel NS, Donnelly HK, Eisenbart J, Oberoi M, Jain M. Active transforming growth factor-beta1 activates the procollagen I promoter in patients with acute lung injury. Intensive Care Med 2005, 31:121-128. 10.1007/s00134-004-2503-2, 15565360.
29. Walsh J, Absher M, Kelley J. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol 1993, 9:637-644. 10.1165/ajrcmb/9.6.637, 7504929.
30. Rhee CK, Lee SH, Yoon HK, Kim SC, Lee SY, Kwon SS, Kim YK, Kim KH, Kim TJ, Kim JW. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 2011, 82:273-287. 10.1159/000327719, 21659722.
31. Zhao F, Zhang YF, Liu YG, Zhou JJ, Li ZK, Wu CG, Qi HW. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplantation proceedings 2008, 40:1700-1705. 10.1016/j.transproceed.2008.01.080, 18589176.
32. Yi ES, Salgado M, Williams S, Kim SJ, Masliah E, Yin S, Ulich TR. Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury. Inflammation 1998, 22:315-325. 10.1023/A:1022304317111, 9604718.
33. Rhee CK, Kim JW, Park CK, Kim JS, Kang JY, Kim SJ, Kim SC, Kwon SS, Kim YK, Park SH, Lee SY. Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. Int Arch Allergy Immunol 2011, 155:243-251. 10.1159/000321261, 21293142.
34. Kobayashi M, Kubota T, Uemura Y, Taguchi H. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib. Respirology 2009, 14:302-304. 10.1111/j.1440-1843.2008.01467.x, 19192229.
35. El-Agamy DS. Nilotinib ameliorates lipopolysaccharide-induced acute lung injury in rats. Toxicol Appl Pharmacol 2011, 253:153-160. 10.1016/j.taap.2011.03.023, 21473879.
36. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clinical rheumatology 2003, 22:329-332. 10.1007/s10067-003-0716-3, 14576993.
37. Eklund KK, Lindstedt K, Sandler C, Kovanen PT, Laasonen L, Juurikivi A, Wolff H, Mykkanen M, Joensuu H. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol 2008, 14:294-296. 10.1097/RHU.0b013e318188b1ce, 18824923.
38. Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003, 35:362-367. 10.1080/07853890310001339, 12952023.
39. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990, 348:550-552. 10.1038/348550a0, 2147233.
40. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101:311-320. 10.1172/JCI1368, 508569, 9435302.
41. Giebelen IA, van Westerloo DJ, LaRosa GJ, de Vos AF, van der Poll T. Local stimulation of alpha7 cholinergic receptors inhibits LPS-induced TNF-alpha release in the mouse lung. Shock 2007, 28:700-703.
42. Chen Z, Zhang X, Chu X, Song K, Jiang Y, Yu L, Deng X. Preventive effects of valnemulin on lipopolysaccharide-induced acute lung injury in mice. Inflammation 2010, 33:306-314. 10.1007/s10753-010-9186-3, 20221680.
43. Shi JR, Mao LG, Jiang RA, Qian Y, Tang HF, Chen JQ. Monoammonium glycyrrhizinate inhibited the inflammation of LPS-induced acute lung injury in mice. Int Immunopharmacol 2010, 10:1235-1241. 10.1016/j.intimp.2010.07.004, 20637836.
44. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15:255-273. 10.1016/j.cytogfr.2004.03.006, 15207816.